Description:

CALGB: 40302 ADVERSE EVENT FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5A8CF0A-505E-3C78-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5A8CF0A-505E-3C78-E034-0003BA3F9857

Keywords:
Versions (4) ▾
  1. 8/26/12
  2. 1/9/15
  3. 1/9/15
  4. 7/8/15
Uploaded on:

July 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

CALGB_40302_AE_FRM NCT00390455

Details

If data are amended, circle amended items and check the "Yes" box. If submitting by mail, retain a copy for your records.

CALGB clinical trial administrative data
Are data amended
Patient demographics
Adverse Event Expedited Reporting System filed?
Has an AdEERS been filed (with Central Office based on an event reported below)
Expected Adverse Events
CTC AE Attribution Code (^2)
CTC AE Attribution Code (^2)
Back to the top of the page 

Similar models